Rapid Micro Biosystems Inc-A (NASDAQ:RPID) Posts Mixed Q3 2025 Results, Raises Full-Year Guidance

Rapid Micro Biosystems Inc-A (NASDAQ:RPID announced its financial results for the third quarter of 2025, revealing a performance that narrowly missed analyst expectations on the top and bottom lines. The company concurrently announced a significant new customer order and raised its full-year financial guidance, creating a mixed picture that appears to be reflected in muted pre-market trading activity.

Third Quarter Financial Results Versus Estimates

The company reported total revenue of $7.8 million for the quarter ended September 30, 2025. While this represents a 3% increase compared to the same period in 2024, it fell just short of market expectations.

• Reported Revenue: $7.84 million
• Estimated Revenue: $7.91 million
• Reported Non-GAAP EPS: -$0.26
• Estimated Non-GAAP EPS: -$0.25

The slight miss on both key metrics indicates that while the company's growth trajectory continues, the pace was marginally slower than analysts had projected for the quarter.

Market Reaction and Recent Performance

The immediate market reaction to the earnings release appears cautious. In pre-market trading, the stock is down approximately 1.5%, suggesting investors are weighing the earnings miss against the positive guidance raise. This short-term movement follows a period of weakness for the stock, which has declined nearly 23% over the past month. The performance over the last week and two weeks has been relatively flat, indicating a period of consolidation leading up to the earnings announcement.

Key Announcements and Raised Outlook

Beyond the quarterly figures, the earnings release contained significant operational and forward-looking news. The company highlighted a record multi-system customer order, a strong signal of market acceptance for its flagship Growth Direct system. More consequentially for the full-year picture, management raised its guidance for both revenue and system placements. This upward revision provides a more optimistic frame around the slight Q3 miss, suggesting company leadership sees stronger momentum heading into the final quarter of the year. This improved outlook can be contrasted with the current full-year analyst sales estimate of $32.7 million.

Looking Ahead to Q4 and Full-Year 2025

Analysts have already set expectations for the upcoming quarter, which will be critical for the company to meet its revised guidance.

• Q4 2025 Estimated Revenue: $10.02 million
• Q4 2025 Estimated EPS: -$0.22

The company's own raised guidance will now set a higher bar for the fourth quarter. Investors will be watching closely to see if the momentum from the record order and management's confidence translates into financial performance that meets or exceeds these analyst estimates for Q4 and achieves the company's own heightened full-year targets.

For a detailed breakdown of historical earnings, future estimates, and analyst projections, review the complete earnings and estimates data for RPID.

Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The content presented is based on publicly available information and should not be the sole basis for any investment decision.